Just hitting the wires on HealthTechMovers.com, these 5 consumer stocks just received "Buy" ratings. These are very volatile stocks so please do your own research before you make any investments. While we may list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers.
this another site
Krystal Biotech, KRYS
Krystal Biotech (KRYS) has seen a 43.43% increase in price over the past month and a 47.09% increase in price over the past three months, and a 54.98% increase since the 6 month mark, leading to a market cap of $3.11B. Analysts are giving this stock a strong-buy consensus with a target price of $141.00, giving an upside of 22.12%. Volume has been high lately with an average 10 day volume of 566,193, and if the bullish analyst consensus continues, this stock is likely to continue to trend upwards.
Click here to get the full story on KRYS stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
BridgeBio Pharma, BBIO
BridgeBio Pharma (BBIO) has seen an overall decrease of 5.30% in price over the last month, and an increase of 20.40% over the past three months, and an increase of 46.74% since the 6 month mark, giving it a market cap of $2.21B. Analysts are giving this stock a strong buy consensus and setting a target price of $29.57, giving an upside of 118.39%. Volume has been high lately with 1,317,725 average 10 day volume, and with the strong consensus of analysts this stock could continue to be bullish.
Click here to get the full story on BBIO stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Geron, GERN
Geron (GERN) has an average volume of 5,372,493, with a one month gain of 32.11%, a three month gain of 16.91%, and a six month gain of 40.09%, leading to a market cap of $1.65B. Analysts have a strong buy consensus on this stock setting a target price of $5.00, giving it a realistic 50.60% upside. Volume has increased slightly lately and the positive analyst sentiment suggests that this stock could continue to trend upwards in the near future.
Click here to get the full story on GERN stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
iTeos Therapeutics, ITOS
iTeos Therapeutics (ITOS) has recently seen a decrease of 8.92% in price over the last day. The stock has seen a one month gain of 31.37%, a three month gain of 1.92%, and a six month loss of 10.42%, bringing it to a market cap of $645.54M. Analysts have returned a moderate buy consensus and have set a target price of $39.67, offering an impressive 141.30% upside. Volume has been low lately, but this could be offset by the bullish analyst consensus and the stock could continue to show potential gains in the future.
Click here to get the full story on ITOS stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
OptimizeRx, OPRX
OptimizeRx (OPRX) has a market cap of $243.38M and an average 10 day volume of 124,555. Over the past month, this stock has seen a negative 5.46% change in its price, a negative 20.39% change over the past three months, and negative 32.62% change since the 6 month mark. Analysts have given this stock a strong-buy consensus and set a target price of $21.50, offering investors an upside of 56.93%. With its low price target upside and the analysts consensus, this stock is likely to continue to trend downwards.
Click here to get the full story on OPRX stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
We appreciate your continued interest in our analyst ratings email newsletter and we hope that you remain informed on all the latest financial developments and news. We look forward to providing you with more comprehensive analyst ratings and analysis in the near future.
Thank you and have a great day.
this is great
